MX9804793A - Acidos arilsulfonamido-hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral-alfa y de metaloproteinasa de matriz. - Google Patents
Acidos arilsulfonamido-hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral-alfa y de metaloproteinasa de matriz.Info
- Publication number
- MX9804793A MX9804793A MX9804793A MX9804793A MX9804793A MX 9804793 A MX9804793 A MX 9804793A MX 9804793 A MX9804793 A MX 9804793A MX 9804793 A MX9804793 A MX 9804793A MX 9804793 A MX9804793 A MX 9804793A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- tnf
- arylsulphonamido
- substituted
- treatment
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 title 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 206010064390 Tumour invasion Diseases 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000009400 cancer invasion Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US866195P | 1995-12-15 | 1995-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9804793A true MX9804793A (es) | 1998-10-31 |
Family
ID=21732933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9804793A MX9804793A (es) | 1995-12-15 | 1998-06-15 | Acidos arilsulfonamido-hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral-alfa y de metaloproteinasa de matriz. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5770624A (enExample) |
| EP (1) | EP0873312B1 (enExample) |
| JP (1) | JP4112004B2 (enExample) |
| KR (1) | KR100452941B1 (enExample) |
| CN (1) | CN1173948C (enExample) |
| AR (1) | AR005068A1 (enExample) |
| AT (1) | ATE219058T1 (enExample) |
| AU (1) | AU709489B2 (enExample) |
| BR (1) | BR9612136B1 (enExample) |
| CZ (1) | CZ292431B6 (enExample) |
| DE (1) | DE69621830T2 (enExample) |
| DK (1) | DK0873312T3 (enExample) |
| EA (1) | EA002019B1 (enExample) |
| ES (1) | ES2178724T3 (enExample) |
| HU (1) | HU226123B1 (enExample) |
| IL (1) | IL124524A (enExample) |
| MX (1) | MX9804793A (enExample) |
| NO (1) | NO311643B1 (enExample) |
| NZ (1) | NZ324287A (enExample) |
| PL (1) | PL187136B1 (enExample) |
| PT (1) | PT873312E (enExample) |
| SK (1) | SK78998A3 (enExample) |
| TR (1) | TR199801105T2 (enExample) |
| TW (1) | TW453995B (enExample) |
| WO (1) | WO1997022587A1 (enExample) |
| ZA (1) | ZA9610532B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| EA003294B1 (ru) * | 1995-12-08 | 2003-04-24 | Агурон Фармасьютикалс, Инк. | Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения |
| US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| IL127496A0 (en) * | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
| US6492394B1 (en) | 1998-12-22 | 2002-12-10 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US6753337B2 (en) * | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| BR0007784A (pt) | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| GB9918684D0 (en) * | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| GB9922825D0 (en) * | 1999-09-25 | 1999-11-24 | Smithkline Beecham Biolog | Medical use |
| AU2001237939A1 (en) * | 2000-02-08 | 2001-08-20 | Gulgun Tezel | Methods for treating glaucoma |
| US6531128B1 (en) * | 2000-02-08 | 2003-03-11 | Pharmacia Corporation | Methods for treating glaucoma |
| US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
| KR20030005230A (ko) * | 2000-03-21 | 2003-01-17 | 더 프록터 앤드 갬블 캄파니 | Ｎ-치환된 메탈로프로테아제 저해제를 함유하는 탄소환식측쇄 |
| CA2401728A1 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Difluorobutyric acid metalloprotease inhibitors |
| WO2001070682A2 (en) * | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Carbocyclic side chain containing metalloprotease inhibitors |
| RU2245876C2 (ru) | 2000-03-21 | 2005-02-10 | Дзе Проктер Энд Гэмбл Компани | Производные сульфонамидов и фармацевтическая композиция на их основе |
| JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| GB0208176D0 (en) * | 2002-04-09 | 2002-05-22 | Novartis Ag | Organic compounds |
| AU2003253346A1 (en) * | 2002-07-29 | 2004-02-23 | Novartis Ag | Use or arylsulfonamido-substituted hydroxamid acid matrix metalloproteinase inhibitors for the treatment or prevention of toxemia |
| AU2003294917A1 (en) * | 2002-12-20 | 2004-07-14 | Novartis Ag | Device and method for delivering mmp inhibitors |
| US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
| EP1592458A1 (en) | 2003-02-10 | 2005-11-09 | GE Healthcare Limited | Diagnostic imaging agents with mmp inhibitory activity |
| EP1622617A2 (en) * | 2003-02-11 | 2006-02-08 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| DK2041181T3 (da) * | 2006-06-08 | 2011-08-29 | Helmholtz Zentrum Muenchen | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi |
| FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| EP3199534B1 (en) | 2016-02-01 | 2018-09-05 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
| AU690703B2 (en) * | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
-
1996
- 1996-11-26 TW TW085114549A patent/TW453995B/zh not_active IP Right Cessation
- 1996-12-03 DK DK96942307T patent/DK0873312T3/da active
- 1996-12-03 BR BRPI9612136-0A patent/BR9612136B1/pt not_active IP Right Cessation
- 1996-12-03 KR KR10-1998-0704349A patent/KR100452941B1/ko not_active Expired - Fee Related
- 1996-12-03 NZ NZ324287A patent/NZ324287A/en unknown
- 1996-12-03 ES ES96942307T patent/ES2178724T3/es not_active Expired - Lifetime
- 1996-12-03 IL IL12452496A patent/IL124524A/en not_active IP Right Cessation
- 1996-12-03 DE DE69621830T patent/DE69621830T2/de not_active Expired - Lifetime
- 1996-12-03 CN CNB961990171A patent/CN1173948C/zh not_active Expired - Fee Related
- 1996-12-03 CZ CZ19981854A patent/CZ292431B6/cs not_active IP Right Cessation
- 1996-12-03 WO PCT/EP1996/005362 patent/WO1997022587A1/en not_active Ceased
- 1996-12-03 PT PT96942307T patent/PT873312E/pt unknown
- 1996-12-03 PL PL96327450A patent/PL187136B1/pl not_active IP Right Cessation
- 1996-12-03 AT AT96942307T patent/ATE219058T1/de not_active IP Right Cessation
- 1996-12-03 SK SK789-98A patent/SK78998A3/sk unknown
- 1996-12-03 AU AU11406/97A patent/AU709489B2/en not_active Ceased
- 1996-12-03 TR TR1998/01105T patent/TR199801105T2/xx unknown
- 1996-12-03 HU HU0000214A patent/HU226123B1/hu not_active IP Right Cessation
- 1996-12-03 EP EP96942307A patent/EP0873312B1/en not_active Expired - Lifetime
- 1996-12-03 EA EA199800529A patent/EA002019B1/ru not_active IP Right Cessation
- 1996-12-03 JP JP52245797A patent/JP4112004B2/ja not_active Expired - Fee Related
- 1996-12-10 US US08/763,273 patent/US5770624A/en not_active Expired - Lifetime
- 1996-12-13 ZA ZA9610532A patent/ZA9610532B/xx unknown
- 1996-12-13 AR ARP960105665A patent/AR005068A1/es unknown
-
1998
- 1998-06-05 NO NO19982579A patent/NO311643B1/no unknown
- 1998-06-15 MX MX9804793A patent/MX9804793A/es not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69610709D1 (de) | N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen | |
| GEP20033140B (en) | Substituted Bicyclic Derivatives Useful as Anticancer Agents | |
| NZ285846A (en) | Arylsulphonamido-substituted hydroxamic acids and preparation and medicaments useful for inhibiting metalloproteinases | |
| DK0606046T3 (da) | Arylsulfonamido-substituerede hydroxamsyrederivater | |
| MY113586A (en) | Aylsulfonylamino hydroxamic acid derivatives | |
| YU37499A (sh) | Derivati arilsulfonil hidroksamske kiseline | |
| MY117896A (en) | Quinazoline derivatives | |
| CA2218503A1 (en) | Arylsulfonyl hydroxamic acid derivatives | |
| MY121754A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
| MY120235A (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
| GEP20022653B (en) | Processes and Intermediates for Preparing Anti-Cancer Compounds | |
| WO2001018171A3 (en) | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | |
| CA2283643A1 (en) | Certain cyclic thio substituted acylaminoacid amide derivatives | |
| TR199801115T2 (xx) | Kinazolin t�revleri. | |
| GEP20033117B (en) | Hydroxy Pipecolate Hydroxamic Acid Derivatives as MMP Inhibitors, Pharmaceutical Compositions Containing Them and Their Use for Treatment of Diseases caused by MMP | |
| UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| EP0818442A3 (en) | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor | |
| DK0738270T3 (da) | Dihydropyrazolopyrroler | |
| EA199800529A1 (ru) | Альфа-замещенные арилсульфонамидогидроксамовые кислоты в качестве ингибиторов tnf-альфа и матричных металлопротеиназ | |
| IL104154A0 (en) | Saccharin derivatives,their preparation and pharmaceutical compositions containing them | |
| HUP9802762A2 (hu) | Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
| TNSN98083A1 (fr) | Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| HUP0402577A2 (hu) | Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra | |
| CA2340138A1 (en) | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GD | Licence granted | ||
| MM | Annulment or lapse due to non-payment of fees |